Kardigan, Inc. (KARD) · Nov 6, 2026 · Other events
Enrollment complete — 156 participants enrolled; Week 48 topline expected in 2H 2027
Kardigan’s KATALYST-AV enrollment is complete, but its revised 48-week endpoint delays definitive ataciguat data and raises execution questions.
Kardigan is a clinical-stage cardiovascular company advancing three Phase 2b-or-later programs, with ataciguat aimed at slowing moderate calcific aortic stenosis where no approved disease-modifying therapy exists. Its prior public plan called for a 24-week ataciguat readout in the first half of 2027, so this filing is an execution milestone but also changes how—and when—the main evidence will arrive.
Enrollment completion advances the program, but does not provide an efficacy readout. KATALYST-AV has reached all 156 participants, removing recruitment as the immediate operational hurdle.
The protocol change makes the eventual test more informative but pushes out the decisive answer. The primary calcium endpoint will now be assessed at Week 48 alongside valve-area and cardiac-function measures, with topline data expected in the second half of 2027 rather than the previously signaled 24-week interim readout in the first half.
The new evidence improves Phase 3 planning but exposes uncertainty around the original calcium thesis. In roughly 45,000 real-world patients, aortic valve area—not baseline calcium—was the strongest progression predictor; AVC did not distinguish rapid from normal progressors. That supports enriching a future trial around cardiac damage and disease progression, but it also means a single calcium-based signal may be harder to interpret than the earlier development narrative implied.
Bottom line: This is a real development advance, not a clinical win: recruitment is finished and the Phase 3 strategy is getting sharper, but the key ataciguat efficacy answer is deferred to a longer follow-up period with greater endpoint uncertainty.
Phase 3 development-plan update, first half 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!